Market Overview

UPDATE: Jefferies & Company Initiates Coverage on Antares Pharma with Buy Rating, $5 PT

Related ATRS
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Morning Market Losers

In a report published Wednesday, Jefferies & Company initiated coverage on Antares Pharma (NASDAQ: ATRS) with a Buy rating and $5.00 price target.

Jefferies noted, “We are initiating on ATRS with a Buy and a 12-month $5 price target. ATRS is a needle auto-injector innovator transitioning from a device technology partner to an integrated commercial-stage drug company. The primary driver is a self-injected once-weekly form of methotrexate for RA (NDA filed 12/17/12) with better safety and efficacy potential. In the meantime, several already-partnered drugs should fund pre-launch preparations in '13.”

Antares Pharma closed on Tuesday at $3.82.

Latest Ratings for ATRS

Oct 2014JMP SecuritiesInitiates Coverage onOutperform
May 2014OppenheimerMaintainsOutperform
Oct 2013JefferiesMaintainsBuy

View More Analyst Ratings for ATRS
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Initiation Analyst Ratings


Related Articles (ATRS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content